Boston Partners Acquires 223,816 Shares of Enovis Co. (NYSE:ENOV)

Boston Partners increased its holdings in Enovis Co. (NYSE:ENOV) by 27.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,048,532 shares of the company’s stock after purchasing an additional 223,816 shares during the quarter. Boston Partners’ holdings in Enovis were worth $46,034,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of the business. UMB Bank n.a. boosted its position in Enovis by 128.2% during the fourth quarter. UMB Bank n.a. now owns 778 shares of the company’s stock valued at $34,000 after acquiring an additional 437 shares during the last quarter. Pinnacle Bancorp Inc. boosted its position in Enovis by 54.5% during the fourth quarter. Pinnacle Bancorp Inc. now owns 850 shares of the company’s stock valued at $37,000 after acquiring an additional 300 shares during the last quarter. FMR LLC boosted its position in Enovis by 20.5% during the third quarter. FMR LLC now owns 2,840 shares of the company’s stock valued at $122,000 after acquiring an additional 484 shares during the last quarter. XTX Topco Ltd bought a new stake in Enovis during the third quarter valued at $217,000. Finally, Legacy Capital Wealth Partners LLC bought a new stake in Enovis during the fourth quarter valued at $228,000. Institutional investors own 98.45% of the company’s stock.

Analysts Set New Price Targets

Separately, Needham & Company LLC cut their price target on shares of Enovis from $65.00 to $64.00 and set a “buy” rating on the stock in a research report on Thursday, February 27th.

Enovis Price Performance

Shares of NYSE ENOV opened at $39.41 on Thursday. The firm’s 50-day moving average price is $42.97 and its 200-day moving average price is $43.59. Enovis Co. has a 1-year low of $35.14 and a 1-year high of $62.79. The firm has a market capitalization of $2.24 billion, a P/E ratio of -17.99 and a beta of 2.05. The company has a current ratio of 2.27, a quick ratio of 1.12 and a debt-to-equity ratio of 0.40.

Enovis (NYSE:ENOV) last announced its quarterly earnings data on Wednesday, February 26th. The company reported $0.98 earnings per share for the quarter, beating the consensus estimate of $0.92 by $0.06. Enovis had a negative net margin of 5.95% and a positive return on equity of 4.39%. The firm had revenue of $560.98 million for the quarter, compared to analyst estimates of $555.14 million. Equities research analysts anticipate that Enovis Co. will post 2.79 earnings per share for the current fiscal year.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.